
Porphyria - Pipeline Insight, 2025
Description
DelveInsight’s, Porphyria - Pipeline Insight, 2025,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Porphyria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Porphyria: Overview
Erythropoietic Protoporphyria (EPP) is an inherited disorder of the heme biosynthetic pathway that results from mutations of the ferrochelatase (FECH) gene or, less commonly X-Linked Protoporphyria (XLP) that results from mutations in the aminolevulinic acid synthase-2 (ALAS2) gene. Both EPP and XLP are characterized by accumulation of protoporphyrin in blood, erythrocytes and tissues and cutaneous photosensitivity. EPP and XLP usually present early in childhood with extremely painful phototoxic reactions which are preceded by a “prodrome” of tingling, stinging, and/or burning of sun-exposed skin. The onset of prodromal symptoms after direct sun exposure varies but may occur in less than 10 minutes.
""Porphyria - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Porphyria pipeline landscape is provided which includes the disease overview and Porphyria treatment guidelines. The assessment part of the report embraces, in depth Porphyria commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Porphyria collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
Porphyria Emerging Drugs
Further product details are provided in the report……..
Porphyria: Therapeutic Assessment
This segment of the report provides insights about the Porphyria drugs segregated based on following parameters that define the scope of the report, such as:
Porphyria: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Porphyria therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Porphyria drugs.
Porphyria Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Porphyria: Overview
Erythropoietic Protoporphyria (EPP) is an inherited disorder of the heme biosynthetic pathway that results from mutations of the ferrochelatase (FECH) gene or, less commonly X-Linked Protoporphyria (XLP) that results from mutations in the aminolevulinic acid synthase-2 (ALAS2) gene. Both EPP and XLP are characterized by accumulation of protoporphyrin in blood, erythrocytes and tissues and cutaneous photosensitivity. EPP and XLP usually present early in childhood with extremely painful phototoxic reactions which are preceded by a “prodrome” of tingling, stinging, and/or burning of sun-exposed skin. The onset of prodromal symptoms after direct sun exposure varies but may occur in less than 10 minutes.
""Porphyria - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Porphyria pipeline landscape is provided which includes the disease overview and Porphyria treatment guidelines. The assessment part of the report embraces, in depth Porphyria commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Porphyria collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence R&D Porphyria. The therapies under development are focused on novel approaches to treat/improve Porphyria.
Porphyria Emerging Drugs
- Dersimelagon: Mitsubishi Tanabe Pharma
- DISC-0974: Disc Medicine
Further product details are provided in the report……..
Porphyria: Therapeutic Assessment
This segment of the report provides insights about the Porphyria drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Porphyria
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Molecule Type
- Small molecule
- Cell Therapy
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Porphyria: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Porphyria therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Porphyria drugs.
Porphyria Report Insights
- Porphyria Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Porphyria drugs?
- How many Porphyria drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Porphyria?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Porphyria therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Porphyria and their status?
- What are the key designations that have been granted to the emerging drugs?
- Clinuvel Pharmaceuticals
- Mitsubishi Tanabe Pharma
- Gilead Sciences
- Disc Medicine
- Atlas Molecular Pharma
- Afamelanotide PII
- Dersimelagon PIII
- Ledipasvir/sofosbuvir
- DISC-1459
- Ciclopirox
Table of Contents
65 Pages
- Introduction
- Executive Summary
- Porphyria: Overview
- What is Porphyria?
- Types of Porphyria
- Causes
- Epidemiology and Risk Factors
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Porphyria– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Dersimelagon: Mitsubishi Tanabe Pharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Afamelanotide: Clinuvel Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Porphyria Key Companies
- Porphyria Key Products
- Porphyria- Unmet Needs
- Porphyria- Market Drivers and Barriers
- Porphyria- Future Perspectives and Conclusion
- Porphyria Analyst Views
- Porphyria Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.